NASDAQ:NBIX Neurocrine Biosciences (NBIX) Stock Price, News & Analysis → The system that called 2023’s top 7 stocks is at it again… (From WealthPress) (Ad) Free NBIX Stock Alerts $139.15 -0.94 (-0.67%) (As of 11:16 AM ET) Add Compare Share Share Today's Range$138.69▼$144.7050-Day Range$130.40▼$143.7452-Week Range$89.04▼$148.37Volume239,625 shsAverage Volume841,939 shsMarket Capitalization$13.85 billionP/E Ratio57.50Dividend YieldN/APrice Target$139.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Neurocrine Biosciences alerts: Email Address Neurocrine Biosciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.70 Rating ScoreUpside/Downside0.8% Downside$142.38 Price TargetShort InterestHealthy2.44% of Shares Sold ShortDividend StrengthN/ASustainability-2.61Upright™ Environmental ScoreNews Sentiment0.49Based on 33 Articles This WeekInsider TradingSelling Shares$25.81 M Sold Last QuarterProj. Earnings Growth31.20%From $4.84 to $6.35 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.37 out of 5 starsMedical Sector98th out of 909 stocksBiological Products, Except Diagnostic Industry11th out of 156 stocks 2.4 Analyst's Opinion Consensus RatingNeurocrine Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.74, and is based on 17 buy ratings, 6 hold ratings, and no sell ratings.Amount of Analyst CoverageNeurocrine Biosciences has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 4.0 Short Interest Percentage of Shares Shorted2.44% of the outstanding shares of Neurocrine Biosciences have been sold short.Short Interest Ratio / Days to CoverNeurocrine Biosciences has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Neurocrine Biosciences has recently decreased by 2.02%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldNeurocrine Biosciences does not currently pay a dividend.Dividend GrowthNeurocrine Biosciences does not have a long track record of dividend growth. Previous Next 2.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreNeurocrine Biosciences has received a 24.32% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Valbenazine", "Elagolix", and "Opicapone" products. See details.Environmental SustainabilityThe Environmental Impact score for Neurocrine Biosciences is -2.61. Previous Next 1.9 News and Social Media Coverage News SentimentNeurocrine Biosciences has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 33 news articles for Neurocrine Biosciences this week, compared to 8 articles on an average week.Search InterestOnly 2 people have searched for NBIX on MarketBeat in the last 30 days. This is a decrease of -90% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Neurocrine Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -72% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Neurocrine Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $25,806,409.00 in company stock.Percentage Held by InsidersOnly 4.60% of the stock of Neurocrine Biosciences is held by insiders.Percentage Held by Institutions92.59% of the stock of Neurocrine Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Neurocrine Biosciences are expected to grow by 31.20% in the coming year, from $4.84 to $6.35 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neurocrine Biosciences is 59.29, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 135.48.Price to Earnings Ratio vs. SectorThe P/E ratio of Neurocrine Biosciences is 59.29, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 168.33.Price to Book Value per Share RatioNeurocrine Biosciences has a P/B Ratio of 6.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Insider FinancialThousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.Simply tap here now to subscribe and start getting "Insider Financial Advantage" About Neurocrine Biosciences Stock (NASDAQ:NBIX)Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.Read More NBIX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NBIX Stock News HeadlinesApril 18, 2024 | insidertrades.comInsider Selling: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Sells 19,818 Shares of StockApril 16, 2024 | insidertrades.comThe 5 Stocks Most Sold By Insiders This Year (NBIX)April 24, 2024 | Insider Financial (Ad)Thousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.March 26, 2024 | insidertrades.comIngrid Delaet Sells 5,000 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) StockApril 24, 2024 | finance.yahoo.comNeurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia CommunityApril 24, 2024 | investorplace.com3 Red-Hot Biotech Rockets Blasting Off in 2024April 24, 2024 | americanbankingnews.comNeurocrine Biosciences (NASDAQ:NBIX) Given Hold Rating at Needham & Company LLCApril 24, 2024 | americanbankingnews.comNeurocrine Biosciences (NBIX) Scheduled to Post Quarterly Earnings on WednesdayApril 24, 2024 | TradeSmith (Ad)The A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...April 23, 2024 | finance.yahoo.comDoes Neurocrine, The No. 1 Biotech Stock, Have The Next Ketamine On Its Hands?April 23, 2024 | finance.yahoo.comNo. 1 Biotech Stock Neurocrine Launches Higher On Depression Treatment WinApril 23, 2024 | markets.businessinsider.comNeurocrine's Phase 2 SAVITRI Study Meets Primary Endpoint For NBI-1065845 In Adults With MDDApril 22, 2024 | finance.yahoo.com10 Best Performing Biotech ETFs in 2024April 20, 2024 | americanbankingnews.comNeurocrine Biosciences, Inc. to Post FY2025 Earnings of $6.58 Per Share, William Blair Forecasts (NASDAQ:NBIX)April 20, 2024 | americanbankingnews.comContrasting Taysha Gene Therapies (NASDAQ:TSHA) and Neurocrine Biosciences (NASDAQ:NBIX)April 19, 2024 | americanbankingnews.comEric Benevich Sells 19,818 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) StockApril 19, 2024 | americanbankingnews.comWedbush Reiterates Outperform Rating for Neurocrine Biosciences (NASDAQ:NBIX)April 18, 2024 | investing.comSentia and Neurocrine extend collaboration on peptide therapeuticsApril 17, 2024 | nasdaq.comValidea Detailed Fundamental Analysis - NBIXApril 16, 2024 | globenewswire.comNxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568April 15, 2024 | americanbankingnews.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives Average Rating of "Moderate Buy" from AnalystsApril 10, 2024 | prnewswire.comNeurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial ResultsApril 5, 2024 | uk.investing.comNeurocrine begins phase 2 trial for depression drugApril 5, 2024 | investing.comNeurocrine Biosciences executive sells shares worth over $37kApril 3, 2024 | markets.businessinsider.comWells Fargo Reaffirms Their Hold Rating on Neurocrine (NBIX)April 3, 2024 | finance.yahoo.comIs Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Recent Performance Tethered To Its Attractive Financial Prospects?April 3, 2024 | prnewswire.comNeurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive DisorderSee More Headlines Receive NBIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/07/2024Today4/24/2024Next Earnings (Confirmed)5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:NBIX CUSIP64125C10 CIK914475 Webwww.neurocrine.com Phone(858) 617-7600Fax858-617-7602Employees1,400Year FoundedN/APrice Target and Rating Average Stock Price Target$142.38 High Stock Price Target$200.00 Low Stock Price Target$100.00 Potential Upside/Downside-0.3%Consensus RatingModerate Buy Rating Score (0-4)2.70 Research Coverage23 Analysts Profitability EPS (Most Recent Fiscal Year)$2.42 Trailing P/E Ratio57.89 Forward P/E Ratio28.94 P/E GrowthN/ANet Income$249.70 million Net Margins13.23% Pretax Margin17.60% Return on Equity12.85% Return on Assets9.02% Debt Debt-to-Equity RatioN/A Current Ratio2.45 Quick Ratio2.40 Sales & Book Value Annual Sales$1.89 billion Price / Sales7.39 Cash Flow$2.70 per share Price / Cash Flow51.83 Book Value$22.72 per share Price / Book6.17Miscellaneous Outstanding Shares99,510,000Free Float94,930,000Market Cap$13.94 billion OptionableOptionable Beta0.25 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Kevin C. Gorman Ph.D. (Age 66)CEO & Director Comp: $1.9MMr. Matthew C. Abernethy (Age 43)Chief Financial Officer Comp: $1.04MMr. Darin M. Lippoldt Esq. (Age 58)Chief Legal Officer & Corporate Secretary Comp: $921.01kMr. Kyle W. Gano Ph.D. (Age 51)Chief Business Development & Strategy Officer Comp: $921.52kDr. Eiry Wyn Roberts M.D. (Age 59)Chief Medical Officer Comp: $1.04MDr. Jude Onyia Ph.D. (Age 59)Chief Scientific Officer Comp: $621.66kJane SorensenHead of Investor RelationsMs. Julie S. Cooke (Age 58)Chief Human Resources Officer Mr. Eric S. Benevich (Age 59)Chief Commercial Officer Comp: $805kMr. David Warren Boyer (Age 44)Chief Corporate Affairs Officer More ExecutivesKey CompetitorsAcceleron PharmaNASDAQ:XLRNRepligenNASDAQ:RGENExelixisNASDAQ:EXELMomenta PharmaceuticalsNASDAQ:MNTAHalozyme TherapeuticsNASDAQ:HALOView All CompetitorsInsiders & InstitutionsAssenagon Asset Management S.A.Bought 22,177 shares on 4/24/2024Ownership: 0.339%Rice Hall James & Associates LLCSold 5,200 shares on 4/23/2024Ownership: 0.127%Amalgamated BankSold 12,814 shares on 4/23/2024Ownership: 0.055%Louisiana State Employees Retirement SystemBought 1,000 shares on 4/23/2024Ownership: 0.029%Covenant Asset Management LLCBought 535 shares on 4/23/2024Ownership: 0.028%View All Insider TransactionsView All Institutional Transactions NBIX Stock Analysis - Frequently Asked Questions Should I buy or sell Neurocrine Biosciences stock right now? 23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last year. There are currently 6 hold ratings and 17 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" NBIX shares. View NBIX analyst ratings or view top-rated stocks. What is Neurocrine Biosciences' stock price target for 2024? 23 Wall Street research analysts have issued 1-year price targets for Neurocrine Biosciences' stock. Their NBIX share price targets range from $100.00 to $200.00. On average, they predict the company's share price to reach $142.38 in the next twelve months. This suggests that the stock has a possible downside of 0.8%. View analysts price targets for NBIX or view top-rated stocks among Wall Street analysts. How have NBIX shares performed in 2024? Neurocrine Biosciences' stock was trading at $131.76 at the beginning of 2024. Since then, NBIX stock has increased by 8.9% and is now trading at $143.47. View the best growth stocks for 2024 here. When is Neurocrine Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our NBIX earnings forecast. How can I listen to Neurocrine Biosciences' earnings call? Neurocrine Biosciences will be holding an earnings conference call on Wednesday, May 1st at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link. How were Neurocrine Biosciences' earnings last quarter? Neurocrine Biosciences, Inc. (NASDAQ:NBIX) posted its earnings results on Wednesday, February, 7th. The company reported $1.44 EPS for the quarter, beating analysts' consensus estimates of $1.13 by $0.31. The company had revenue of $515.20 million for the quarter, compared to analysts' expectations of $518.52 million. Neurocrine Biosciences had a trailing twelve-month return on equity of 12.85% and a net margin of 13.23%. The firm's quarterly revenue was up 25.0% compared to the same quarter last year. During the same period in the prior year, the company posted $0.88 EPS. What ETFs hold Neurocrine Biosciences' stock? ETFs with the largest weight of Neurocrine Biosciences (NASDAQ:NBIX) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE), iShares Neuroscience and Healthcare ETF (IBRN), First Trust NYSE Arca Biotechnology Index Fund (FBT), Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD), VanEck Biotech ETF (BBH), Goldman Sachs Future Health Care Equity ETF (GDOC), Virtus LifeSci Biotech Products ETF (BBP) and Invesco Bloomberg Pricing Power ETF (DEF). What is Kevin C. Gorman's approval rating as Neurocrine Biosciences' CEO? 11 employees have rated Neurocrine Biosciences Chief Executive Officer Kevin C. Gorman on Glassdoor.com. Kevin C. Gorman has an approval rating of 97% among the company's employees. This puts Kevin C. Gorman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Neurocrine Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Netflix (NFLX), AbbVie (ABBV), Walt Disney (DIS), Tesla (TSLA), Block (SQ) and Salesforce (CRM). Who are Neurocrine Biosciences' major shareholders? Neurocrine Biosciences' stock is owned by many different institutional and retail investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.51%), Assenagon Asset Management S.A. (0.34%), Sumitomo Mitsui Trust Holdings Inc. (0.25%), Los Angeles Capital Management LLC (0.25%), Rice Hall James & Associates LLC (0.13%) and Portman Square Capital LLP (0.00%). Insiders that own company stock include Darin Lippoldt, David W Boyer, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, George J Morrow, Ingrid Delaet, Jude Onyia, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Leslie V Norwalk, Malcolm Lloyd-Smith, Matt Abernethy, Neurocrine Biosciences Inc, Richard F Pops, Stephen A Sherwin and William H Rastetter. View institutional ownership trends. How do I buy shares of Neurocrine Biosciences? Shares of NBIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NBIX) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”AltimetryFed launches fourth dollar overhaulStansberry ResearchTiny Biotech Stock Wins $75 Billion PatentBehind the MarketsI’m afraid WWIII is a very real possibility Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
